Document:

EMPLOYMENT AGREEMENT

THIS EMPLOYMENT  AGREEMENT (the  "Agreement") is made effective as of January 1,
2001,  by  and  between  GRILL  CONCEPTS,  INC.,  a  Delaware  corporation  (the
"Company") and ROBERT L. SPIVAK ("Employee").

                                    RECITALS

WHEREAS,  the Company and  Employee  have  heretofore  entered  into  Employment
Agreements   dated,   January  1,  1993,   January  1,1996  and  January  1,1999
(collectively  the  `'Previous   Agreements"),   setting  forth  the  terms  and
conditions  of the  Company's  employment  of  Employee  as its Chief  Executive
Officer; and

WHEREAS,  the Company and Employee desire that Employee  continue his employment
with the  Company as its Chief  Executive  Officer  and to replace  its  current
agreement,  pursuant  to  and  in  accordance  with  the  terms  and  conditions
hereinafter set forth in this Agreement;

NOW,  THEREFORE,  in  consideration  of  the  mutual  covenants  and  agreements
contained in this Agreement, the parties hereby agree as follows:

1.   EMPLOYMENT
     ----------

     1.1 The Company hereby employs Employee as its Chief Executive  Officer for
a term of three (3)  years,  commencing  as of  January 1, 2001 and ending as of
December 31, 2004 (the "Term"); provided, however, that the Term may be extended
by the mutual  written  agreement of the parties.  Employee  hereby accepts such
position, upon the terms and conditions set forth in this Agreement.

     1.2  During the Term,  Employee  shall  devote his full time,  energies and
skills to the performance of his duties hereunder,  which shall include, but not
be limited to, the active development, management and operation of the Company's
business.

     1.3  During the Term, Employee shall not, directly or indirectly,  alone or
as a member of a partnership or other association, or as an officer, director or
stockholder,  be engaged in or concerned  with any other duties or pursuits in a
business activity which complete,  directly or indirectly,  with the business of
the  Company  without  the  written  consent of the  Company,  other than owning
securities  in a  publicly  traded  company,  provided  that such  ownership  by
Employee  does not exceed ten percent  (10%) of any class of  securities of such
company.

     1.4 In the course of Employee's  employment  hereunder,  it is  anticipated
that  Employee  may  from  time  to  time  be  allowed  access  to  confidential
information  and trade secrets  (collectively  the  "Confidential  Information")
owned by the  Company  and  used in the  course  of its  business.  The  parties
acknowledge and agree that there is a competitive value and confidential  nature
with respect to the  Confidential  Information,  and that  material  damage will
result to the Company if any of the  Confidential  Information is disclosed to a
third party. Employee therefore agrees that during the Term, and for a period of
one (1) year thereafter,  Employee will not, directly or indirectly, disclose or
use any of the  Confidential  Information  except as  required  in the  ordinary
course of the  company's  business  and  Employee's  employment  hereunder.  All
records, files, documents and materials relating to the Company's business which
Employee  shall  prepare,  use or be provided  with during the Term shall be and
remain the sole  property  of the  Company,  and shall not be  removed  from the
Company's  premises or otherwise utilized by Employee for other than the benefit
of the Company without the Company's written consent.

     1.5   Employee  acknowledges  and  agrees  that in the event of a breach by
Employee  of any of the  provisions  of  paragraphs  1.3 and 1.4 above,  that in
addition  to any other  remedies  it may have at law or in equity,  the  Company
shall be entitled to  injunctive  relief,  without the  necessity of proving the
inadequacy of such other remedies.

<PAGE>

     2. SALARY. Employee shall receive an annual base salary during each year of
the Term of this Agreement as follows:

                               Year One:        $225,000
                               Year Two:        $235,000
                               Year Three:      $250,000

     Such salary  shall be payable in monthly or in such other  installments  on
the payroll dates established for the Company's other employees. All payments of
salary  hereunder  shall be subject to the  deduction of such payroll  taxes and
similar deductions as required by law.

     3. OTHER COMPENSATION. Employee shall be entitled to the following benefits
and other compensation during the Term:

          3.1 Vacation. Five (5) weeks vacation during each year of the Term, at
     such times or times as shall be mutually  agreed upon between  Employee and
     the Company; provided, however, that Employee may not accumulate any unused
     vacation time from one employment year to the next during the Term.

          3.2  Automobile.  Unlimited  use of an  automobile of a make and model
     commensurate  with Employee's  position as Chief  Executive  Officer of the
     Company  hereunder  and  consistent  with that  provided to Employee by the
     Company  in the past.  The  Company  shall  pay all  expenses  for  repair,
     maintenance and insurance for such automobile.

          3.3 Travel and Entertainment.  Unlimited  reimbursement by the Company
     of  Employee  for  entertainment,  dining and travel  expenses  incurred by
     Employee in the course of his performing his duties hereunder.

          3.4  Expense  Allowance.   In  addition  to  the  reimbursement  under
     paragraph  3.3  above,  Employee  shall be  entitled  to a monthly  expense
     allowance to be used by Employee in his sole  discretion,  in an amount not
     to exceed One Thousand Five Hundred Dollars ($1,500) per month.

          3.5 Health Benefits. During the Term and any extension thereof, unless
     the Executive is terminated for cause, each of the Executive and his spouse
     (or  widow)  shall be  entitled  to  receive,  at the sole  expense  of the
     Company,  such benefits,  including  without  limitation,  participation in
     group life,  health,  accident,  disability,  liability or  hospitalization
     insurance plans, pension plans, severance plans or retirement plans, as the
     Company  currently  makes  available  to its  highest  level  of  executive
     employees as a group or as such  programs  and  benefits  are  amended.  In
     addition,  the Company  will,  at its own expense,  continue to provide the
     benefits  referred to in Paragraph  3.5 to the Executive and his spouse (or
     widow) for five (5) years after the  expiration of the Term,  such benefits
     to be provided  regardless  of the reason for any  separation of employment
     including,  but not limited to, the  Executive's  death or disability,  but
     excluding  termination for cause. The Company  represents and warrants that
     the  benefits  to the  Executive  and his spouse (or  widow)  described  in
     paragraph  3.5 shall at all times be  substantially  as  favorable  or more
     favorable  to the  Executive  and his spouse (or widow) as those  currently
     provided.  In the event that the  Company is unable to  continue to provide
     the benefits required by this paragraph 3.5 through continued participation
     in the  Company's  plans,  the Company is  required  to provide  comparable
     benefits for the Executive  and his spouse (or widow) from another  source.
     After  benefits  are no longer  required to be  provided  at the  Company's
     expense to the Executive and his spouse (or widow) pursuant to this Section
     3.5,  each of the  Executive and his spouse (or widow) shall be entitled to
     participate in the Company's health and hospitalization  insurance plans as
     described in Section 3.5 at his and/or her own expense,  for as long as the
     Company's plans permit.

     3.6 Life Insurance.  Term life insurance coverage in the face amount of One
Million Dollars  ($1,000,000),  the premiums and all other costs for which shall
be paid in full by the Company.

     3.7 Stock Options. Company hereby grants to Employee one hundred thousand (
100,000) shares of stock at a price of $ per share, ten percent in excess of the
selling price of the stock on December 31,2000, in accordance with provisions of
the Company's  Stock Option Plan (the "Plan').  The options will vest  one-third
(1/3)  at the end  of2001,  one-third  (1/3)  at the end  of2002  and the  final
one-third at the end of2003.

                                       2
<PAGE>

     3.8 Bonus Plan.  Executive shall be eligible for a performance-based  bonus
of a maximum of fifty percent (50%) of salary.  Metrics shall be  established by
the Compensation Committee of the Board of Directors on or before February 28 of
each year.

     3.9 Other  Benefits.  Such other  benefits as  Employee  may be eligible to
receive in accordance with the Company's  announced employee benefit programs in
effect  from time to time,  including,  but not  limited  to,  paid sick  leave,
participation  in qualified  pension and/or profit  sharing plans,  split-dollar
life  insurance   policies,   reimbursement   for  uninsured  medical  expenses,
non-qualified   and/or  incentive  stock  options,   and/or  unfunded   deferred
compensation.  Nothing  contained in this paragraph shall be deemed to restrict,
limit or affect any stock  options  which may have  previously  been  granted to
Employee

     4.  TERMINATION.  This Agreement shall terminate upon the occurrence of any
of the following:

         4.1 The expiration of the Term hereof.

         4.2 The mutual written consent of the parties hereto.

         4.3 The death of Employee.

         4.4 The permanent disability of Employee,  as such term is defined
             in paragraph 6 below.

         4.5 For cause, at the option of the Company, as provided in paragraph 5
             below

     Nothing  contained  in this  paragraph 4 shall be  construed,  however,  to
abrogate  the  payment  by  the  Company  to  Employee  or  Employee's  personal
representative  or heirs,  as the case may be, of any  benefits or  compensation
which  had  accrued  and  was  due to  Employee  prior  to  termination  of this
Agreement.

     5.  TERMINATION  FOR CAUSE.  The Company shall have the right,  at its sole
election,  to terminate  Employee's  employment hereunder at any time during the
Term for cause,  which, for purposes of this Agreement,  shall be constituted by
any of the following events:

          5.1 Employee is convicted  by any  federal,  state or local  authority
     with (i) an act of dishonesty; or (ii) an act involving moral turpitude; or
     (iii)an act  constituting  a felony;  or (iv) narcotics  addiction;  or (v)
     habitual intemperance.

          5.2 The continued  failure by Employee,  following written notice from
     the Company, to fulfill Employee's  obligations under or comply with any of
     the provisions of this Agreement.

     Any election by the Company to  terminate  this  Agreement  for cause under
paragraphs 5.1 or 5.2 above shall be made by giving  Employee  written notice to
such effect by certified or registered mail at Employee's last known address, or
by personal delivery of such notice to Employee;  provided, however, that in the
event Employee is either convicted or pleads guilty or nolo contendere to any of
the  charges set forth in  paragraph  5.1 above,  the  Company  may  immediately
terminate this Agreement  thereupon.  The waiver by the Company of any such acts
of Employee as described in this  paragraph 5 shall not be construed as a waiver
of any subsequent acts by Employee.

6.   PERMANENT DISABILITY.
     ---------------------

         6.1 The terms  "permanent  disability" as used in this Agreement  shall
mean six ( 6) months of substantially  continuous  disability . Disability shall
be deemed  "substantially  continuous" if, as a practical matter,  Employee,  by
reason of mental or  physical  health,  is  unable to  sustain  reasonably  long
periods of  substantial  performance  of his duties.  Frequent  long  illnesses,
though  different  from a preceding  illness and though  separated by relatively
short periods of Employee's performance of his duties hereunder, shall be deemed
to be "substantially" continuous.

         6.2 In the event of any dispute concerning the permanent  disability of
Employee,  the Company and  Employee  shall each select a physician  licensed to
practice  medicine  in the State of  California,  who shall then  select a third
physician  so licensed.  Such  selection  shall be made within  thirty (30) days
after  Employee  gives  notice to the  Company  that he disputes  the  Company's
determination  that Employee is permanently  disabled.  The  determination  of a
majority  of the three (3)  physicians  concerning  whether or not  Employee  is
permanently  disabled  shall be  conclusive  and binding upon the parties.  Such
determination  shall be made by the three (3) physicians  within sixty (60) days
of their  selection.  In the event that either the Company or Employee  fails to
select a physician within the prescribed time period, then either it or he shall
be  deemed  to have  waived  its or his  right to do so,  and the  determination
regarding  Employee's  permanent  disability hereunder shall be made by the sole
physician selected.

                                       3
<PAGE>

     7. ASSIGNMENT. Employee may not assign or otherwise transfer this Agreement
or any of Employee's rights, duties,  interests or obligations hereunder without
the written consent of the Company.

     8. ENTIRE  AGREEMENT.  This  Agreement  embodies the entire  agreement  and
understanding between the parties with respect to the subject matter hereof, and
supersedes all prior and contemporaneous  agreements and understandings relating
to such subject matter, whether oral or written, including,  without limitation,
the Previous Agreements. The parties acknowledge and agree that neither has made
any representations  with respect to the subject matter of this Agreement except
as specifically set forth in this Agreement.

     9.  AMENDMENT.  This  Agreement  may not be  amended  except  by a  written
document executed by the parties.

     10.  SEVERABILITY.  If any  provision  of  this  Agreement  shall  be  held
unenforceable  as applied to any  circumstance,  the remainder of this Agreement
and  the  application  of  such  provision  to  other   circumstances  shall  be
interpreted so as best to affect the intent of the parties.  The parties further
agree to replace any such unenforceable  provision with an enforceable provision
(and to take such other action) which will achieve, to the extent possible,  the
purposes of the unenforceable provision.

     11.  GOVERNING LAW. This Agreement shall be governed by and construed under
the laws of the State of California.

     l2.  ARBITRATION.  Any dispute  arising  under the terms of this  Agreement
shall be submitted to binding arbitration under the Commercial Arbitration Rules
of the American  Arbitration  Association  (the  Rules').  Any hearing under the
Rules shall take place at Los Angeles, California, in accordance with Rule 11 of
the Rules.  The hearing shall be before one (1)  arbitrator  in accordance  with
Rule 17 of the Rules;  provided,  however,  that in the event of a claim made in
excess of One Hundred Thousand Dollars (S 100,000),  the hearing shall be before
three (3)  arbitrators,  in accordance with the Rules. The provisions of Section
1283.05 of the California Code of Civil Procedure are incorporated into and made
a part of this Agreement,  except that subparagraph (e) of Section 1283.05 shall
not apply. Depositions in any arbitration hereunder may be noticed in accordance
with the  California  Code of Civil  Procedure,  and  leave to do so need not be
requested by the arbitrator or arbitrators. Any award rendered by the arbitrator
pursuant to this Agreement and the Rules shall be enforced in the Superior Court
of the  County of Los  Angeles in and for the State of  California  as the court
having sole jurisdiction over the arbitration.

     13.  ATTORNEYS'  FEES.  In  any  arbitration  or  action  to  enforce  this
Agreement,   the  prevailing  party  shall  be  entitled  to  recover  from  the
non-prevailing  party  all  reasonable  costs,  including,  without  limitation,
attorneys' fees.

     l4.  ADDITIONAL  DOCUMENTS.  The parties  agree to execute such  additional
documents  and perform  such other acts as may be necessary  or  appropriate  to
achieve the purposes of this Agreement.

     15.  NON-WAIVER.  No waiver by a party of any failure by the other party to
keep any provision of this  Agreement  shall be deemed a waiver of any preceding
or succeeding breach of the same or any other provision.

     16. BINDING EFFECT. Subject to paragraph 7 above, this Agreement is binding
upon  and  shall  inure to the  benefit  of the  parties  and  their  respective
successors, assigns, heirs, and legal representatives.

                                       4
<PAGE>

     17. NOTICE.  Any notice or other  communication  given  hereunder  shall be
deemed sufficient if in writing and sent by registered or certified mail, return
receipt requested, addressed to the parties as indicated below:

                  If to the Company:

                           11661 San Vicente Boulevard, #404
                           Los Angeles, California 90049

                  If to Employee:

                           ll66l San Vicente Boulevard, #404
                           Los Angeles, California 90049

or to such other  address as the parties may  designate  in writing  pursuant to
this  paragraph.  Notice  shall  be  deemed  to have  been  given on the date of
mailing, except notices of change of address, which shall be deemed to have been
given when received.

     18.   COUNTERPARTS.   This  Agreement  may  be  executed  in  one  or  more
counterparts and/or by facsimile,  each of which shall be deemed an original but
all of which together shall  constitute one and the same  instrument.  Facsimile
signatures  shall be  accepted  by the  parties as valid and  binding in lieu of
original signatures; however, if facsimile signatures are presented by any party
in lieu of original signatures,  within two (2) business days after execution of
the Agreement such party shall also deliver to counsel for the other  party(ies)
an original signature signed by that party.

     19. W AIVER OF CONFLICT OF  INTEREST.  The  parties  acknowledge  that this
Agreement was  originally  prepared by the law firm of Herzog,  Fisher,  Flame &
Grayson  (the  Firm') at the  request of the  Company.  The Firm has not however
represented  either party in connection  with the terms  hereof.  In view of the
fact that the Firm  (and/or one or more of its  individual  members)  has in the
past  rendered  legal  services to and  represented  and will continue to render
legal services to, represent and/or be involved with the Company and/or Employee
in  connection  with the Company  and other  matters,  there is a potential  for
conflicts  of  interest.  The  parties  acknowledge  that they are aware of such
conflicts of interest and the potential adverse effects to them which may result
therefrom,  and,  notwithstanding same, hereby consent to the Firm's preparation
of this Agreement and waive any potential  conflicts of interest with respect to
or against  the Firm in  connection  therewith.  Further,  both the  Company and
Employee  acknowledge that all of the terms of this Agreement were negotiated by
the parties without the Firm's participation in same, both parties being advised
by the Firm that  independent  legal  advisors  should be consulted  relative to
same. In connection  with the foregoing,  the parties  acknowledge  that each of
them has had an  opportunity  to have this  Agreement  reviewed  by  independent
counsel,  and that each of the  parties  is aware of and  understands  the form,
content and legal  effect of this  Agreement  and their  rights and  obligations
hereunder .

     IN WITNESS WHEREOF, the parties have executed this Agreement as of the date
first above written.

               The Company:                GRILL CONCEPTS, INC.,
                                           a Delaware corporation

                                           By: /s/
                                              -----------------------------
                                           Its: Chairman

               Employee:                      /s/
                                             ------------------------------
                                              Robert L. Spivak<PAGE>

Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

                                                                    Exhibit 10.1

                        BIOPROCESSING SERVICES AGREEMENT

This bioprocessing services agreement dated the 16 day of March, 2001
("Agreement") is made between Dendreon Corporation, a Delaware Corporation
("Sponsor") having its principal place of business at 3005 First Avenue,
Seattle, Washington, 98121 and Covance Biotechnology Services Inc., a Delaware
Corporation ("CBSI"), having its principal place of business at 6051 George
Watts Hill Drive, P.O. Box 13865, Research Triangle Park, NC 27709-3865.

Witnesseth
WHEREAS, CBSI provides a fall range of bioprocessing services to the
biopharmaceutical industry, including process development, fermentation, cell
culture, separation/purification, bioanalytical chemistry, quality control,
quality assurance, and regulatory affairs, and

WHEREAS, Sponsor desires CBSI to perform services pursuant to the terms of this
Agreement related to the production of the material known as [ * ] antigen used
in the manufacture of APC8015 and CBSI desires to perform such services,

NOW, THEREFORE, in consideration of the above statements and other good and
valuable consideration, the sufficiency and receipt of which are hereby
acknowledged, the parties hereto agree as follows:

Section 1.
Definitions
a)  Biological Materials means Product, [ * ], including, but not limited to,
    virus stock and any working host cell bank and working virus bank to be
    generated by CBSI pursuant to the Scope.

b)  Bulk Product means purified, formulated Product.

c)  CBSI's Facility means CBSI's laboratories and equipment at Research Triangle
    Park and Cary, North Carolina.

d)  CBSI's Proprietary Information means all information imparted by or for CBSI
    to Sponsor under the Agreement, including technical information, [ * ] and
    business plans.

e)  cGMP means the U.S. Food and Drug Administration current Good Manufacturing
    Practice.

                                       1
<PAGE>

f)  Other Products means, singularly and collectively, antigens used in the
    manufacture of Sponsor's [ * ] products.

g)  Process means Sponsor's small scale cGMP method and means of manufacturing
    [ * ] antigen for Phase I/II/III clinical trials [ * ] using [ * ] and
    [ * ].

h)  Process Consumables means raw materials and other substances and materials
    with which to perform the Program as specified in the Scope.

i)  Process Inventions means inventions and know-how relating to [ * ]
    methods and processes discovered by [ * ] in [ * ] and scientific, technical
    and other information known to [ * ] from time to time including such
    information [ * ].

j)  Product means Sponsor's [ * ] recombinant protein prostate tumor antigen.

k)  Program means the services CBSI will perform for Sponsor in accordance with
    the Scope.

l)  Sponsor's Proprietary Information means all Biological Materials, all
    information imparted by or for Sponsor to CBSI under the Agreement,
    including technical information, records, data, reports, test results,
    business plans and the Process except for [ * ].

m)  Scope means the detailed Scope of Work attached as Appendix One.

n)  Sponsor Collaborator means any entity with which Sponsor has entered into or
    enters into an agreement, a purpose of which is to commercialize the Product
    developed or produced under this Agreement or Other Products.

o)  Unnamed Other Products means products other than the Product developed or
    produced under this Agreement and other than Other Products.

Section 2.
Scope of Work
a)  CBSI will perform the Program for Sponsor in accordance with the Scope at
    CBSI's Facility.

b)  CBSI will, at Sponsor's request, consult with Sponsor in any development of
    the Program design in a manner consistent with current regulatory
    guidelines. However, CBSI does not warrant that the Program results will
    satisfy the requirements of any regulatory agencies at the time of
    submission of Program results to such agencies.

c)  CBSI's performance of the Program according to the Scope will be based on
    technical information provided by or for the Sponsor. This information will
    be translated into development and/or manufacturing documents (development
    plans, batch records, and specifications) which will be reviewed and
    approved by the Sponsor. These documents will form the sole basis upon which
    the Program will be performed. CBSI makes no

[ * ] = Certain confidential information contained in this document, marked by
        brackets, has been omitted and filed separately with the Securities and
        Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange
        Act of 1934, as amended.

                                       2
<PAGE>

    warranties that the execution of the Program in accordance with the Scope
    and these documents will result in any specific quantity, quality or
    biochemical characteristic of Product.

Section 3.
Program Performance
CBSI shall provide facilities, supplies, and staff necessary to complete the
Program as provided in the Scope, as it may be modified as provided herein, and
in accordance with the terms of this Agreement.  In the event of any conflict,
the terms of this Agreement shall control.

CBSI will appoint a CBSI representative (the "Program Manager") to be
responsible for the completion of the Program by CBSI.  The Program Manager will
coordinate performance of the Program with a representative designated by
Sponsor (the "Sponsor Representative"), which representative shall have
responsibility over all matters relating to performance of the Program on behalf
of Sponsor.  Unless otherwise agreed in the Scope, all communications between
CBSI and the Sponsor regarding the conduct of the Program pursuant to the Scope
shall be addressed to or routed through the Program Manager and Sponsor
Representative, directly.  CBSI and Sponsor may, at their discretion, change the
Program Manager and the Sponsor Representative, respectively, during the course
of the Program.

Section 4.
Program Materials
a)  Sponsor will provide CBSI with sufficient amounts of Biological Materials,
    Process Consumables and all documentation and such other data as may be
    necessary to apprise CBSI of the stability of the Biological Materials and
    Process Consumables, process characteristics, proper storage, manufacturing
    and safety requirements. Sponsor will also provide CBSI with all necessary
    information to effect the reliable transfer of the Process from Sponsor to
    CBSI.

b)  Upon completion of the Program, all Biological Materials in the possession
    of CBSI will be properly and promptly returned by CBSI to Sponsor at
    Sponsor's expense, destroyed (with Sponsor's permission) or retained by CBSI
    in compliance with regulatory requirements.

Section 5.
Compliance with Government Regulations
a)  CBSI will perform the Program in accordance with the Scope, and with its
    understanding of cGMP when appropriate to do so as and set forth in the
    Scope. Subject to paragraph b. of Section 5 below, CBSI will also comply in
    all material respects with all applicable government regulatory requirements
    concerning cGMP.

b)  Should applicable government regulatory requirements be changed, CBSI will
    make every reasonable effort to satisfy the new requirements. In the event
    that compliance with such new regulatory requirements necessitates a
    material change in the Scope for the

[ * ] = Certain confidential information contained in this document, marked by
        brackets, has been omitted and filed separately with the Securities and
        Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange
        Act of 1934, as amended.

                                       3
<PAGE>

    Program, CBSI will submit to Sponsor a revised technical and cost proposal
    for Sponsor's acceptance prior to making any changes in the Scope or the
    Program.

c)  In the event of a conflict in government regulations, Sponsor will
    designate, in writing, which regulations shall be followed by CBSI in its
    performance of the Program.

Section 6.
Facility Visits
Sponsor's representatives may visit CBSI's facility to inspect and audit the
Program during business hours in accordance with the `Guidelines for Client
Visits' attached as Appendix Two.  CBSI will assist Sponsor in scheduling such
visits which will be in compliance with CBSI's requirement to protect
confidentiality of other clients.

Section 7.
Compensation
a)  The estimated budget for the Program is [ * ] as specified in the Scope,
    provided that such budget is subject to adjustment if (i) Sponsor executes
    this Agreement later than [ * ] after the date CBSI has executed this
    Agreement and (ii) the Biological Materials, Process Consumables or other
    data or information required to conduct the Program are supplied or provided
    more than [ * ] after the date CBSI has executed this Agreement.

b)  Sponsor shall pay the [ * ] within [ * ] of Sponsor's execution of this
    Agreement and the remaining payments within [ * ] after achieving the
    mutually agreed payment dates or milestones as set forth below.

c)  CBSI will invoice Sponsor for Activities in Sections [ * ] of the attached
    Scope on a monthly basis as follows:

       i)  CBSI will invoice Sponsor based on the [ * ] at a rate of [ * ] for
           the activities included in Sections [ * ] of the attached Scope.
           Process Consumables will be invoiced separately [ * ] as per
           paragraph e) of this Section 7.

      ii)  CBSI will invoice Sponsor at a rate of [ * ] for the [ * ] of work
           performed in support of the activities included in the following
           sections of the Scope, provided that the work is performed before
           [ * ]: Sections: [ * ]. Work performed on or after [ * ] will be
           invoiced to Sponsor at [ * ] rate.

     iii)  The [ * ] rate includes Process Consumables during the [ * ], up to
           and including work at the [ * ], with the exception of [ * ]. For
           production at the [ * ], Process Consumables will be invoiced
           separately [ * ] as per paragraph e) of this Section 7.

d)  Sponsor shall make payments of the price for each batch, in amounts,
    respectively, as will be set forth in the Scope by amendment, for the
    activities included in Sections [ * ] and [ * ] of the attached Scope. Each
    such amended amount shall be established

[ * ] = Certain confidential information contained in this document, marked by
        brackets, has been omitted and filed separately with the Securities and
        Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange
        Act of 1934, as amended.

                                       4
<PAGE>

    following [ * ] and [ * ]. The estimated price for manufacturing and quality
    activities as set forth in the Scope as of the date of this Agreement is
    based on the [ * ] and the [ * ] provided in the Scope. In the event that
    any of the [ * ] are not valid, or the [ * ] are revised, or there is a
    change in the [ * ], the price for manufacturing and quality activities and
    the price for each batch to be set forth by amendment shall be determined by
    calculating, in accordance with [ * ], the increase or decrease, as the case
    may be, in the period of time required in CBSI's facilities, [ * ] and
    adjusted [ * ]. Such payments shall be made as follows:

       i)  [ * ] price per batch, upon commencement of each [ * ] batch of
           Product in accordance with batch records as articulated in the Scope.

      ii)  [ * ] price per batch upon completion of [ * ] in the [ * ] for
           each batch of the Product .

     iii)  [ * ] price per batch of Bulk Product following [ * ] of each batch.

      iv)  Notwithstanding the payments called for in sub-sections i), ii) and
           iii), in the event a batch [ * ] as defined in the batch record, and
           a [ * ], then Sponsor shall be responsible for payment of [ * ].
           Provided further, that in the event a batch [ * ], Sponsor will
           [ * ]; in the event that a batch [ * ], Sponsor will [ * ]; in the
           event that a batch [ * ] and [ * ], then Sponsor will [ * ].

       v)  In the event a batch [ * ], or for any [ * ] as defined in Section
           [ * ] of this Agreement, Sponsor will [ * ] as set forth in sub-
           sections i), ii) and iii) above.

d)   For any Process Consumables needed for the Program that exceed [ * ], CBSI
     will notify Sponsor prior to purchase and Sponsor will be invoiced
     separately.

e)   A handling fee equal to [ * ] of CBSI's actual cost of Process Consumables
     purchased for the Program will be added to Process Consumables invoices.
     Subcontractor charges, will be invoiced in the month that CBSI is invoiced
     by the subcontractor.

f)  Late payments are subject to an interest charge of one and one-half percent
    (1 1/2%) per month.  Any payments that are greater than [ * ] past due
    constitute a breach of this Agreement.

Section 8.
Change Orders
a)  The total estimated budget for the Program specified in Section 7(a) of this
    Agreement and the individual budget components and time estimates specified
    in the Scope are subject to a number of general and program specific
    assumptions. The program specific assumptions relate to the [ * ] and [ * ],
    [ * ], if any, and other matters relating to the [ * ] (the "Program
    Assumptions"). CBSI also assumes that the Sponsor will cooperate and

[ * ] = Certain confidential information contained in this document, marked by
        brackets, has been omitted and filed separately with the Securities and
        Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange
        Act of 1934, as amended.

                                       5
<PAGE>

    perform its obligations under the Agreement and Scope in a timely manner,
    that no event outside the control of CBSI will occur, including, without
    limitation, the events described in Section 19, and that there are no
    changes to any applicable laws, rules or regulations which materially affect
    the Program (the foregoing assumptions together with the Program
    Assumptions, collectively, the "Assumptions"). In the event that a change in
    or deviation from any of the Assumptions requires a modification of the
    Scope or the Program (each being, a "Modification") then the Scope and the
    Program maybe amended as provided in paragraph b) of this Section 8.

b)  In the event a Modification is identified by the Sponsor or by CBSI, the
    identifying party shall notify the other party as soon as is reasonably
    possible. CBSI shall provide Sponsor with a change order containing an
    estimate of the required Modifications, if any, to the Program budget and
    timeline specified in the Scope within [ * ] of receiving such notice.
    Sponsor shall use reasonable best efforts to respond in writing to such
    change order promptly. If Sponsor does not approve such change order and has
    not terminated the Program but wants the Program to be modified to take into
    account the Modification, then Sponsor and CBSI shall use reasonable best
    efforts to agree on a change order that is mutually acceptable. If
    practicable, CBSI shall continue work on the Program during any such
    negotiations, but shall not commence work with respect to the change order
    unless authorized in writing.

Section 9.
Scheduling
CBSI will make commercially reasonable efforts to begin the [ * ] during [ * ]
provided that, (i) the campaign is inclusive of [ * ] and [ * ] activities as
defined in Sections [ * ] of the attached Scope, (ii) the Agreement is signed
and the Program commences no later than [ * ], (iii) A joint decision to proceed
with the [ * ] portion of the Program is reached no later than  [ * ] with a
minimum of [ * ] lead time from the decision point to the anticipated
commencement of the [ * ], (iv) [ * ] activities begin no later than [ * ], and
(v) all [ * ] and    [ * ] activities proceed according to schedule.

In the event that Sponsor and CBSI determine that CBSI will perform only [ * ]
activities and Sponsor will perform [ * ], CBSI will make commercially
reasonable efforts to begin the [ * ] during [ * ] provided that, (i) activities
to be performed by CBSI during [ * ] are confined to  [ * ] as defined in
Sections [ * ] of the attached Scope, and will only require access to the
[ * ], (ii) CBSI will not perform [ * ] and [ * ] will not be required, (iii)
the Agreement is signed and the Program commences no later than [ * ], (iv) A
[ * ] to proceed with the [ * ] portion of the Program is reached no later
than [ * ] with a minimum of [ * ] lead time from the decision point to the
anticipated commencement of the [ * ], (v) [ * ] activities begin no later
than [ * ], and (vi) all [ * ] and [ * ] activities proceed according to
schedule.

In the event that Sponsor and CBSI determine that CBSI will perform [ * ]
activities [ * ] activities and [ * ], CBSI will make commercially reasonable
efforts to begin the [ * ] for the [ * ] during [ * ] as defined in Sections
[ * ] of the attached Scope, and will make commercially reasonable efforts to
begin [ * ] activities beyond [ * ] for the [ * ] during [ * ] as defined in
Sections [ * ] of the attached Scope, provided that, (i) the Agreement is signed

[ * ] = Certain confidential information contained in this document, marked by
        brackets, has been omitted and filed separately with the Securities and
        Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange
        Act of 1934, as amended.

                                       6
<PAGE>

and the Program commences no later than [ * ], (ii) A [ * ] to proceed with the
[ * ] portion of the Program is reached no later than [ * ] with a minimum of
[ * ] lead time from the decision point to the anticipated commencement of the
[ * ], (iii) [ * ] activities begin no later than [ * ], and (iv) all [ * ]
and [ * ] activities proceed according to schedule.

Section 10.
Confidential Information/Legal Proceedings
a)  CBSI shall not disclose any of the Sponsor's Proprietary Information or any
    information pertaining to the Scope or the Program without Sponsor's written
    permission, unless such disclosure: 1) is to an affiliate of CBSI who is
    under a similar obligation to keep such information confidential and is
    participating in the Program or otherwise has a need to know such
    information; 2) is or becomes publicly available through no fault or other
    conduct of CBSI; 3) is disclosed by a third party entitled to disclose it;
    4) is already known to CBSI as shown by its prior written records; or 5) is
    required by any law, rule, regulation, order decision, decree, subpoena or
    other legal process to be disclosed. If such disclosure is requested by
    legal process, CBSI will make all reasonable efforts to notify Sponsor of
    this request promptly prior to any disclosure to permit Sponsor to oppose
    such disclosure by appropriate legal action.

b)  Sponsor shall not disclose any of CBSI's Proprietary Information without
    CBSI's Written permission unless such disclosure: 1) is to an affiliate of
    Sponsor who is under a similar obligation to keep such information
    confidential and is participating in the Program or otherwise has a need to
    know such information; 2) is or becomes publicly available through no fault
    or other conduct of Sponsor; 3) is disclosed by a third party entitled to
    disclose it; 4) is already known to Sponsor as shown by its prior written
    records; or 5) is required by any law, rule, regulation, order decision,
    decree, subpoena or other legal process to be disclosed. If such disclosure
    is requested by legal process, Sponsor will make all reasonable efforts to
    notify CBSI of this request promptly prior to any disclosure to permit CBSI
    to oppose such disclosure by appropriate legal action.

c)  Sponsor and CBSI will ensure that their respective employees and designees
    who receive access to the other's Proprietary Information are legally
    obligated to maintain its confidentiality and CBSI and Sponsor shall be
    responsible for the compliance of such employees and designees.

d)  CBSI will not transfer any Biological Materials without Sponsor's express
    prior written permission to any third party unless such transfer is to an
    affiliate of CBSI who is participating in the Program and has a need to
    possess such Biological Materials.

Section 11.
Work Product
a)  All work outputs (e.g.  reports) will be prepared on CBSI's standard format
    unless otherwise specified in the Scope.

b)  Sponsor will retain and have sole right, title and interest in and to all
    Biological Materials, raw data, documentation, records, protocols, specimens
    and other reports

[ * ] = Certain confidential information contained in this document, marked by
        brackets, has been omitted and filed separately with the Securities and
        Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange
        Act of 1934, as amended.

                                       7
<PAGE>

    generated as a result of the Program, all of which except as herein
    provided, shall be properly and promptly returned to Sponsor by CBSI at
    Sponsor's request and expense. All such written materials will be archived
    by CBSI for a period of five years following completion of the Program
    unless otherwise specified in the Scope or required by applicable laws or
    regulations. Five years after completion of the Program, all of the
    aforementioned written materials will be sent to the Sponsor and a return
    fee will be charged. The Sponsor may elect to have the materials retained in
    the CBSI Archives for an additional period of time at additional cost. If
    Sponsor chooses to have CBSI dispose of the written materials, a disposal
    fee will be charged. CBSI will continue to retain such written materials as
    may be required by law or for archival purposes.

Section 12.
Inventions and Patents
a)  [ * ] will [ * ], including to the exclusion of [ * ], to [ * ] all
    patentable product improvement inventions discovered by [ * ] employees
    directly as a result of performing the Program under this Agreement (a
    "Product Invention") and [ * ] shall promptly notify [ * ] of the discovery
    of each Product Invention and cooperate and cause its employees to cooperate
    with [ * ] in perfecting [ * ] right, title and interest in and to Product
    Inventions, including the execution of applications, assignments and other
    instruments and the giving of testimony which may be appropriate to apply
    for and obtain Letters Patent of the U.S. or of any foreign country with
    respect to the Product Invention, and [ * ] shall compensate [ * ] for the
    time reasonably devoted to such activities and reimburse it for reasonable
    expenses incurred.

b)  [ * ] shall retain [ * ] rights to any [ * ].

c)  [ * ] will grant to [ * ] a [ * ] license to use and practice each [ * ], to
    include additional terms substantially the same as those attached in
    Appendix Three, for the [ * ] required for [ * ] the Product developed or
    produced under this Agreement. Except as hereinafter described, [ * ] has no
    right, express or implied, to [ * ] any [ * ] without the prior written
    permission of [ * ].

d)  [ * ] will grant to [ * ] the right to [ * ] solely to [ * ] the Product
    developed or produced under this Agreement, to include additional terms
    substantially the same as those attached in Appendix Three, to any [ * ],
    subject to payment to [ * ] by [ * ] of a [ * ] in an amount to be
    determined by application of commercially reasonable criteria to be
    established by the parties through good faith negotiation, and also, without
    any [ * ], in the event of any of the following: (i) the Product and all of
    the rights and assets relating to Product [ * ], in which case such [ * ]
    rights shall [ * ] of the Product; (ii) [ * ] is sold, whether by means of
    an asset sale or stock sale and [ * ] (or its successor) can no longer [ * ]
    herein [ * ] by reason of that sale; (iii) [ * ] can not [ * ] to [ * ]
    demands; provided that [ * ] to [ * ] and [ * ] and any other [ * ] to
             --------
    [ * ] as well as the [ * ] hereof.

e)  In addition, [ * ] will grant to [ * ], upon written request, a [ * ]
    license, to include additional terms substantially the same as those
    attached in Appendix Three, to use [ * ] for the [ * ].

[ * ] = Certain confidential information contained in this document, marked by
        brackets, has been omitted and filed separately with the Securities and
        Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange
        Act of 1934, as amended.

                                       8
<PAGE>

f)  In addition, [ * ] will grant to [ * ] the right to [ * ] solely to [ * ] to
    include additional terms, substantially the same as those attached in
    Appendix Three, to any [ * ], subject to payment to [ * ] by [ * ] of a
    [ * ] in an amount to be determined by application of commercially
    reasonable criteria to be established by the parties through good faith,
    and also, without any [ * ], in the event of any of the following: (i) the
    [ * ] and all of the rights and assets relating to [ * ]; (ii) [ * ] is
    sold, whether by means of an asset sale or stock sale and [ * ] (or its
    successor) can no longer [ * ] herein [ * ] by reason of that sale; (iii)
    [ * ] can not [ * ] to [ * ] demands; provided that [ * ] to [ * ] and
                                          --------
    [ * ] and any other [ * ] to [ * ] as well as the [ * ] hereof.

g)  In addition, [ * ] will grant to [ * ], upon written request, a [ * ]
    license, to include additional terms substantially the same as those
    attached in Appendix Three, to use [ * ] for the [ * ], provided that an
                                                            --------
    amended license shall be required for each [ * ] and such license shall
    specify [ * ]. [ * ] to [ * ] such license for [ * ] in the event that the
    terms of such license conflict with any other then preexisting agreement
    between [ * ] and any third party.

h)  In the event that Sponsor intends to utilize any third party to provide
    services for the development or commercialization of the Product similar to
    those being provided by CBSI hereunder (except as described in Section [ * ]
    or for the development or commercialization of [ * ] and wishes to employ
    [ * ] for such development or commercialization, Sponsor shall grant to
    CBSI a right of first negotiation for a period of [ * ] from the date
    Sponsor notifies CBSI of Sponsor's intent to utilize such third party to
    perform such services under commercially reasonable terms.

i)  CBSI reserves and shall have the right to utilize data generated during the
    course of the Program to support applications, assignments or other
    instruments necessary to apply for and obtain Letters Patent of the U.S. or
    any foreign country with respect to [ * ] so long as no information which
    CBSI is required to keep confidential under this Agreement is disclosed in
    any such application, assignment or other instrument. CBSI shall notify
    Sponsor [ * ] in advance of Sponsor's intent to file, make or create any
    such application, assignment or other instrument.

Section 13.
Independent Contractor
CBSI shall perform the Program as an independent contractor of Sponsor and shall
have complete and exclusive control over CBSI's facilities, equipment, employees
and agents.  Nothing in this agreement or other arrangements for which it is
made shall constitute CBSI, or anyone furnished or used by CBSI in the
performance of the services, as employee, joint venturer, partner, or servant of
Sponsor.

Section 14.
Insurance
CBSI shall secure and maintain in full force and effect throughout the
performance of the Program policies of insurance for (a) Workmen's Compensation,
(b) General Liability, (c) Automobile Liability, and (d) Professional Liability
having policy limits, deductibles and

[ * ] = Certain confidential information contained in this document, marked by
        brackets, has been omitted and filed separately with the Securities and
        Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange
        Act of 1934, as amended.

                                       9
<PAGE>

other terms appropriate to the conduct of CBSI's business in CBSI's sole and
exclusive judgment. Certificates evidencing such insurance will be made
available for examination upon request of the Sponsor.

Section 15.
Default
a)  If CBSI is in default of any of its material obligations under this
    Agreement, then Sponsor shall promptly after becoming aware of such default
    notify CBSI in writing of such default. CBSI shall have a period of [ * ]
    from the date of receipt of such notice within which to cure such default;
    provided that if such default renders the Program invalid or significantly
    impractical of use, then CBSI, shall, at its option, either (1) repeat the
    Program at its cost within a reasonable time period mutually agreed to by
    CBSI and Sponsor or (2) refund the entire contract price paid, including
    amounts paid to CBSI for the Program, amounts paid to CBSI by way of
    reimbursement and amounts paid for Process Consumables by Sponsor (the
    "Contract Price"). If CBSI shall fail to cure such default within the
    specified cure period or successfully repeat the Program as agreed to by
    Sponsor, as the case may be, then this Agreement shall, at Sponsor's option,
    immediately terminate. In the event of such termination, Sponsor's sole
    remedy shall be, in the case where such default has not rendered the Program
    invalid or significantly impractical of use, a reduction in the total
    Contract Price in an amount equal to the difference between (1) the total
    Contract Price and (2) the value of the work properly performed, provided
    however, that under no circumstance shall CBSI be liable to Sponsor in an
    amount that, in aggregate exceeds, the Contract Price paid.

b)  If Sponsor is in default of any of its material obligations under this
    Agreement, CBSI shall promptly notify Sponsor in writing of such default.
    Sponsor shall have a period of [ * ] from the date of receipt of such notice
    within which to cure such default; provided that if Sponsor fails to cure
                                       --------
    such breach within the specified cure period, this Agreement shall, at
    CBSI's option and upon notice to Sponsor, immediately terminate.

c)  NOTWITHSTANDING ANYTHING HEREIN TO THE CONTRARY, UNDER NO CIRCUMSTANCES
    SHALL EITHER PARTY BE ENTITLED TO INCIDENTAL, INDIRECT, CONSEQUENTIAL OR
    SPECIAL DAMAGES ARISING IN CONNECTION WITH THE DEFAULT OR BREACH OF ANY
    OBLIGATION OF THE OTHER PARTY UNDER THIS AGREEMENT.

Section 16.
Dispute Resolution
Should any dispute between Sponsor and CBSI arise under this agreement, Sponsor
and CBSI, through appropriately senior executives, shall first meet and attempt
to resolve the dispute in face-to-face negotiations.  This meeting shall occur
within [ * ] of the time the dispute arises.

If no resolution is reached, Sponsor and CBSI shall, within [ * ] of the first
meeting, attempt to settle the dispute by formal mediation.  If the parties
cannot agree upon a mediator and the

[ * ] = Certain confidential information contained in this document, marked by
        brackets, has been omitted and filed separately with the Securities and
        Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange
        Act of 1934, as amended.

                                       10
<PAGE>

place of mediation, the mediation shall be administered by the American
Arbitration Association in Research Triangle Park, North Carolina.

If no resolution is reached through formal mediation, the dispute shall be
resolved by binding arbitration before a three-arbitrator panel, administered by
the American Arbitration Association, with limited discovery.  Each party shall
select one of the arbitrators and those arbitrators shall select the third.

The venue shall be either Research Triangle Park, North Carolina if the notice
of intent to arbitrate the dispute is first given by Sponsor, or Seattle,
Washington if the notice of intent to arbitrate is first given by CBSI, and the
governing law shall be that of the State of North Carolina in either instance,
without giving effect to conflict of law considerations.  In no event shall
punitive or exemplary damages or attorney's fees be awardable and each party
shall be responsible for it's own attorney's fees.

Notwithstanding the foregoing dispute resolution and governing law provisions,
Sponsor and CBSI shall each retain the right to seek judicial injunctive and
other equitable relief where appropriate.

If CBSI shall be required to provide testimony or records in connection with the
Program pursuant to any legal or administrative process or proceeding by reason
of Sponsor's involvement therein, (other than one which arises out of the
conduct of CBSI as opposed to Sponsor's Product or Sponsor's Program design and
is not a dispute between Sponsor and CBSI), then Sponsor will reimburse CBSI for
its expenses, plus CBSI's standard hourly rate for CBSI's employees or
representatives participating in such process or proceeding.

Section 17.
Indemnification
a)  CBSI shall indemnify Sponsor and its affiliates and their respective current
    and former officers, directors, employees and agents (collectively and
    individually "Sponsor Group") from any loss, cost, damage or expense (a
    "Loss") arising from any lawsuit, action, claim, demand, assessment or
    proceeding (a "Claim") for personal injury to Program participants or
    personal injury to any officer, director, employee or agent of Sponsor or
    property damage arising or occurring during the conduct of the Program as a
    result of CBSI's negligence, gross negligence, intentional misconduct or
    negligent inaction; provided that if such Loss or Claim arises in whole or
    in part as a result of Sponsor Group's negligence, gross negligence,
    intentional misconduct or negligent inaction, then the amount of the Loss
    for which CBSI shall indemnify Sponsor Group pursuant to this Section 17
    shall be reduced by an amount in proportion to the percentage of such Loss
    occurring as a result of Sponsor Group's negligence, gross negligence,
    intentional misconduct or negligent inaction.

b)  Sponsor shall indemnify CBSI and its affiliates and their respective current
    and former officers, directors, employees and agents (collectively and
    individually "CBSI Group") from any Claim or Loss arising from (i) personal
    injury to a participant in the Program or personal injury to any employee of
    the CBSI Group directly or indirectly caused by the

[ * ] = Certain confidential information contained in this document, marked by
        brackets, has been omitted and filed separately with the Securities and
        Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange
        Act of 1934, as amended.

                                       11
<PAGE>

    Biological Materials, (ii) the Agreement, the Program or any aspect thereof
    set forth in the Scope that violates any applicable law, rule, regulation or
    ordinance which violation results in a Loss, (iii) the harmful or otherwise
    unsafe effect of the Product, including, without limitation, a Claim based
    upon Sponsor Group's or any other person's use, consumption, sale,
    distribution or marketing of the Product, (iv) the negligence, gross
    negligence, intentional misconduct or negligent inaction of Sponsor Group in
    the performance of its obligations under this Agreement or Scope related to
    the Program, or (v) the Sponsor Group's violation, non-compliance or non-
    performance of any of the terms of this Agreement; (vi) arising from a
    breach of any third party's intellectual property rights arising from the
    use of Biological Materials, provided that if such Loss or Claim (other
                                 --------
    than a Loss or Claim described in clause (iii) hereof) arises in whole or in
    part from CBSI Group's negligence, gross negligence, intentional misconduct
    or negligent inaction, then the amount of such Loss for which Sponsor shall
    indemnify CBSI Group pursuant to this Section 17 shall be reduced by an
    amount in proportion to the percentage of such Loss occurring as a result of
    CBSI Group's negligence, gross negligence, intentional misconduct or
    negligent inaction. Sponsor shall not indemnify CBSI Group from any Loss
    occurring as a result of the cause described in clause (iii) hereof arising
    solely from the willful misconduct or inaction of CBSI Group.

c)  Upon receipt of notice of any Claim which may give rise to a right of
    indemnity from the other party hereto, the party seeking indemnification
    (the "Indemnified Party") shall give written notice thereof to the other
    party, (the "Indemnifying Party") with a Claim for indemnity. Such Claim for
    indemnity shall indicate the nature of the Claim and the basis therefore.
    Promptly after a claim is made for which the Indemnified Party seeks
    indemnity, the Indemnified Party shall permit the Indemnifying Party, at its
    option and expense, to promptly, and no later than [ * ] days from receipt
    of the notice of claim, assume the complete defense of such Claim. The
    Indemnified Party will have the right to participate in the defense of any
    such Claim, the defense of which is assumed by the Indemnifying Party, at
    its own cost and expense. The Indemnifying Party will conduct the defense of
    any such Claim with due regard for the business interests and potential
    related liabilities of the Indemnified Party and prior to making any
    settlement, shall consult with the Indemnified Party as to the terms of such
    settlement. The Indemnifying Party shall not agree to the entry of a
    judgment against the Indemnified Party or admit to liability on the part of
    the Indemnified Party or agree to non-monetary terms of settlement without
    the Indemnified Party's prior express written consent. The Indemnifying
    Party will not, in defense of any such Claim agree to a settlement thereof,
    without the giving by the claimant or plaintiff to the Indemnified Party a
    full general release from all liability in respect thereof.

d)  The Indemnified Party shall have the right, at its election, to release and
    hold harmless the Indemnifying Party from its obligations of indemnity
    hereunder with respect to such Claim and to itself undertake the complete
    defense of the same in return for payment by the Indemnifying Party to the
    Indemnified Party of the amount of the Indemnifying Party's settlement
    offer. After notice to the Indemnifying Party of the Indemnified Party's
    election to itself undertake the complete defense of such Claim, the
    Indemnified

[ * ] = Certain confidential information contained in this document, marked by
        brackets, has been omitted and filed separately with the Securities and
        Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange
        Act of 1934, as amended.

                                       12
<PAGE>

    Party shall be liable to the Indemnifying Party for such legal or other
    expenses subsequently incurred by the Indemnifying Party in connection with
    the defense thereof at the request of the Indemnified Party. As to those
    Claims with respect to which the Indemnifying Party does not elect to assume
    the complete defense, the Indemnified Party will afford the Indemnifying
    Party an opportunity to participate in such defense at the Indemnifying
    Party's own cost and expense, and will not settle any such Claim in a way
    that directly affects the Indemnifying Party without the consent of the
    Indemnifying Party, which consent shall not be unreasonably withheld.

Section 18.
Warranties, Representations and Disclaimer
Sponsor hereby warrants to CBSI that Sponsor has legal title and/or a valid
license to the Biological Materials, raw material, patents relating to the
Process and the Product and represents that there is no claim of infringement
and that Sponsor knows of no infringement with respect thereto.

Sponsor hereby represents that any raw materials, cell lines, expression
systems, reference standards, or any other materials provided by Sponsor to CBSI
and required for execution of the Program contemplated by this Agreement are, to
the best of Sponsor's knowledge, reasonably possessed under applicable
circumstances, safe and suitable for cGMP use.

Sponsor hereby represents to CBSI that any technical or regulatory information
or documentation, including, but not limited to process details, analytical
methods development reports, technology transfer documents and specifications
provided by Sponsor to CBSI and required for execution of the Program
contemplated by this Agreement are, to the best of Sponsor's knowledge,
reasonably possessed under applicable circumstances, accurate and suitable for
cGMP use.

Sponsor makes NO, AND DISCLAIMS ALL OTHER WARRANTIES AND REPRESENTATIONS OF ANY
KIND, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION, ANY WARRANTY OF
MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE or with respect to the
utility, efficacy, non-toxicity, safety or appropriateness of using the
Biological Materials.

[ * ] = Certain confidential information contained in this document, marked by
        brackets, has been omitted and filed separately with the Securities and
        Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange
        Act of 1934, as amended.

                                       13
<PAGE>

Section 19.
Force Majeure
Either party shall be excused from performing its respective obligations under
this Agreement if its performance is delayed or prevented by any event beyond
such party's reasonable control, including, but not limited to, acts of God,
fire, explosion, weather, disease, war, insurrection, civil strife, riots,
government action, or power failure, provided that such performance shall be
excused only to the extent of and during such disability.  Any time specified
for completion of performance in the Scope falling due during or subsequent to
the occurrence of any such event shall be automatically extended for a period of
time reasonable under all the circumstances to recover from such disability.
CBSI will promptly notify Sponsor if, by reason of any of the events referred to
herein, CBSI is unable to meet any such time for performance specified in the
Scope.  If any part of the Program is invalid as a result of such disability,
CBSI will, upon written request from Sponsor, but at Sponsor's sole cost and
expense, repeat that part of the Program affected by the disability.

Section 20.
Allocation of Resources
If delays in the agreed commencement or performance of the Program occur because
of the Sponsor's inability to supply CBSI with agreed Biological Materials or
any information required to begin or perform the Program within 30 days of such
agreed time, CBSI may reallocate for a period not longer than a period equal to
the period of such delay resources being held for performance of the Program
without incurring liability to Sponsor.

Section 21.
Use of Names
Neither party shall use the name of the other party or the names of the
employees of the other party in any advertising or sales promotional material or
in any commercial publication in a manner designed to promote sales of services
or products without prior written permission of such party,

Section 22.
Termination by Sponsor
a)  Sponsor may at any time for reasons unrelated to circumstances contemplated
    in Section 15 terminate the Program prior to completion by giving [ * ]
    written notice to CBSI. In such event CBSI shall comply with such notice to
    terminate the Program and use its best efforts to reduce cost to Sponsor,
    and Sponsor shall pay CBSI upon receipt of CBSI's invoice all of its costs
    incurred or irrevocably obligated. Sponsor shall also pay CBSI [ * ] and
    [ * ]:

    i)  equal to [ * ] of the [ * ] (Sections [ * ] of the Scope) plus [ * ] if
        the Program is terminated under this Section 22 on or prior to [ * ]; or

    ii) equal to [ * ] of the [ * ] in Section [ * ] of this Agreement if the
        Program is terminated under this Section 22 after [ * ]. Should the
        Scope and the [ * ] be [ * ] of this Agreement, the [ * ] will be
        calculated on the [ * ].

   Such payments, however, shall not be owing if the termination is the result
   of an uncured default.

[ * ] = Certain confidential information contained in this document, marked by
        brackets, has been omitted and filed separately with the Securities and
        Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange
        Act of 1934, as amended.

                                       14
<PAGE>

b)  The termination of this Agreement for any reason shall not relieve either
    party of its obligation to the other for obligations in respect of (i)
    confidentiality of information, (ii) consents for advertising purposes and
    commercial publications (iii) indemnification, and, except as otherwise
    provided herein, (iv) compensation for services performed.

Section 23.
Assignment
This Agreement shall not be assigned in whole or in part by either party without
the prior written consent of the other, which consent shall not be unreasonably
withheld or delayed.  Any attempt to assign this Agreement without such consent
shall be void and of no effect.

Section 24.
Notice
All notices to be given as required in this Agreement shall be in writing and
shall be delivered personally, sent by telecopier, or mailed either by a
reputable overnight carrier or first class mail, postage prepaid, to the parties
at the addresses set forth above or such other addresses as the parties may
designate in writing.  Such notice shall be effective on the date of personal
delivery, the date sent, if by telecopier, the date after delivery if sent by
overnight carrier and on the date received if mailed first class.

Section 25.
Waiver/Severability
No waiver of any provision of this Agreement, whether by conduct or otherwise,
in any one or more instances shall be deemed to be or be construed as a further
or continuing waiver of any such provision, or of any other provision or
condition of this Agreement.  If any provisions hereof shall be determined to be
invalid or unenforceable, the validity and effect of the other provisions of
this Agreement shall not be effected thereby.

Section 26.
Entire Agreement, Modification/Counterparts
This Agreement, including the Scope, set forth the entire agreement between the
parties hereto with respect to the performance of the Program by CBSI for
Sponsor and as such, supersedes all prior and contemporaneous negotiations,
agreements, representations, understandings, and commitments with respect
thereto and shall take precedence over all terms, conditions and provisions on
any purchase order form or form of order acknowledgment or other document
purporting to address the same subject matter.  This Agreement shall not be
waived, released, discharged, changed or modified in any manner except by an
express agreement signed by duly authorized officers of each of the parties
hereto.  This Agreement may be executed in one or more counterparts each of
which shall be deemed an original but all of which together shall constitute one
and the same agreement.

This Agreement becomes effective and binding on both parties on and as of the
last date that the parties hereto have executed this Agreement.  Should terms
contained herein be at variance with the terms and conditions specified in
Sponsor's written acceptance, then the terms and conditions contained herein
take precedence.

[ * ] = Certain confidential information contained in this document, marked by
        brackets, has been omitted and filed separately with the Securities and
        Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange
        Act of 1934, as amended.

                                       15
<PAGE>

Dendreon Corporation                       Covance Biotechnology Services Inc.

By:  /s/ David L. Urdal                    By:  /s/ John H. Brown
    -------------------                        ------------------
Name:  David L. Urdal                      Name:  John H. Brown
       -------------------                        -------------------
Title:  President                          Title:   President / CEO
        -------------------                        -------------------
Date:  3/16/2001                           Date:  16.3.01
       -------------------                        -------------------

[ * ] = Certain confidential information contained in this document, marked by
        brackets, has been omitted and filed separately with the Securities and
        Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange
        Act of 1934, as amended.

                                       16
<PAGE>

                                  Appendix One
                                  ------------

[ * ] = Certain confidential information contained in this document, marked by
        brackets, has been omitted and filed separately with the Securities and
        Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange
        Act of 1934, as amended.

                                       17
<PAGE>

[LOGO OF COVANCE]
--------------------------------------------------------------------------------

Scope of Work for Process
Development, Scale-up and
cGMP Manufacturing of [ * ]

--------------------------------------------------------------------------------
         PREPARED FOR:        Dendreon Corporation (Sponsor)
                              3005 First Avenue
                              Seattle, Washington 98121

          PREPARED BY:        Covance Biotechnology Services, Inc. (CBSI)
                              6051 George Watts Hills Drive
                              Research Triangle Park, NC 27709

       DATE SUBMITTED:        March 16, 2001

Prices and Program duration are estimates and are non-binding and subject to
terms and conditions to be agreed.  Pricing is valid until [ * ].

[ * ] = Certain confidential information contained in this document, marked by
        brackets, has been omitted and filed separately with the Securities and
        Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange
        Act of 1934, as amended.
<PAGE>

TABLE OF CONTENTS

[ * ]

(52 pages of continuous text redacted here)

[ * ] = Certain confidential information contained in this document, marked by
        brackets, has been omitted and filed separately with the Securities and
        Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange
        Act of 1934, as amended.

                                       2
<PAGE>

                                  Appendix Two
                                  ------------

[ * ] = Certain confidential information contained in this document, marked by
        brackets, has been omitted and filed separately with the Securities and
        Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange
        Act of 1934, as amended.

<PAGE>

                         Guidelines for Sponsor Visits

Access to production areas:
--------------------------

During production runs, CBSI shall arrange for Sponsor to have access to the
manufacturing floor with the provision that CBSI reserves the right to limit
access in the event that such access compromises cGMP, safety or reasonable
performance of the work per the Scope.  A CBSI escort will be assigned and will
accompany the Sponsor at all times while in controlled areas of the plant.
During this time it is critical that the visitor:

 .  Follows all GMP / access / gowning / safety procedures as directed by CBSI
   personnel.

 .  Does not touch or operate any equipment in the production

 .  Does not direct manufacturing personnel. Suggestions or recommendations may
   be made to an area Manager or Director.

 .  Does not remove any documentation or in-process data. Requests for
   documentation must be made in writing to an area Manager or Director. Any
   documentation provided in this fashion will be tracked by the area Director.

 .  Makes all requests for additional immediate in-process sampling, in writing
   to the area Manager or Director with full justification, prior to sampling.

 .  Does not enter areas where production is ongoing for another Sponsor.

 .  Does not take any photos inside any CBSI facility. CBSI can provide digital
   photographs as appropriate.

Lack of adherence to these very basic guidelines will result in immediate loss
of access to production areas.

2.  Audits:
-----------

Existing customers:

 .  CBSI will support 1 (one) audit of up to 2 days duration, during each 12
   month period of an active contract agreement, to be billed on a time and
   materials basis or as specified in the contract agreement.

 .  The audit may be performed by the Sponsor or by an external third party, with
   third party costs being at the sole expense of the Sponsor. A maximum of 3
   auditors / Sponsor participants will be allowed to take part in the actual
   audit, due to space limitations and dedicated CBSI personnel availability.

 .  Dates for the audit must be arranged and agreed with CBSI a minimum of one
   month prior to the audit. CBSI reserves the right to make final approval of
   audit dates, based on availability of the facility and appropriate CBSI
   personnel.

 .  Confidentiality agreements must be in place with all parties participating in
   the audit, prior to scheduling the audit.

 .  Three weeks before the audit occurs, a list of areas / topics to be covered
   in the audit will need to be received by CBSI. This will allow CBSI to ensure
   appropriate CBSI personnel

[ * ] = Certain confidential information contained in this document, marked by
        brackets, has been omitted and filed separately with the Securities and
        Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange
        Act of 1934, as amended.
<PAGE>

   availability during the audit, while also ensuring minimal impact to programs
   in production for other Sponsors.

 .  No access will be allowed into areas where production is underway for another
   Sponsor.

 .  Any audit observations being sent to CBSI for review or response must be
   provided by the Sponsor, not directly from a third party auditor. CBSI will
   formally respond to audit findings within 45 days.

 .  All audit observations are confidential, covered in the confidentiality
   agreement between CBSI and the Sponsor, and may not be shared with any other
   party without express written permission.

All third party auditors must also sign confidentiality agreements with CBSI
confirming adherence to this condition and may not share their findings beyond
the Sponsor who contracts the audit, without express written permission from
CBSI.

 .  It may be possible to arrange additional audits during a given year, to be
   billed to the Sponsor on a time-and-materials basis. An estimate of this
   charge can be provided in advance, and will be determined by the scope of the
   audit and, therefore, the resources required to support it.

During audits:

All non-CBSI personnel will be escorted at all times while in controlled areas
of the plant, Process Development or Quality laboratories. During this time it
is critical that the visitor:

 .  Follows all GMP / access / gowning / safety procedures as directed by CBSI
   personnel

 .  Does not direct manufacturing personnel.

 .  Does not touch or operate any equipment in the production or laboratory area.

 .  Does not remove any documentation.

 .  Does not enter areas where production is underway for other Sponsors.

 .  Does not take photos within any CBSI facility. CBSI can provide digital
   photographs as appropriate.

[ * ] = Certain confidential information contained in this document, marked by
        brackets, has been omitted and filed separately with the Securities and
        Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange
        Act of 1934, as amended.
<PAGE>

                                 Appendix Three
                                 --------------

[ * ] = Certain confidential information contained in this document, marked by
        brackets, has been omitted and filed separately with the Securities and
        Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange
        Act of 1934, as amended.

<PAGE>

                                Additional Terms
                                ----------------

 .  "Technology" shall mean those inventions which are made, reduced to practice,
    ----------
   or created by Licensor, any patents that may issue therefrom and all
   intellectual property rights appurtenant thereto, including, without
   limitation, all means, know-how, processes and technology relating to the
   manufacture of product. Copies of any issued patents include within the
   Technology will be provided to Licensee upon issuance.

 .  Technology Transfer. Upon execution of this Agreement the parties shall enter
   -------------------
   into good faith discussions in order to reach a definitive agreement
   concerning the provision of services related to the transfer of the
   manufacturing process. It is contemplated that such services shall include:
   1) release of all technology transfer documents, process specifications, and
   process flow diagrams; 2) access to and review of manufacturing batch
   records; 3) access to appropriate staff to meet and/or consult with
   representatives of the third party manufacturer and 4) analytical methods,
   equipment requirements, development reports, validation plans and reports and
   all other know-how within the Technology. Licensee shall compensate Licensor
   for such Technology transfer services at the Licensor's standard commercial
   rates. Travel and all other out-of-pocket expenses incurred by Licensor will
   be reimbursed by Licensee plus Licensor's standard mark-up for such expense.

 .  WARRANTY DISCLAIMER. LICENSOR MAKES NO REPRESENTATION, GUARANTEE OR WARRANTY,
   -------------------
   EXPRESS OR IMPLIED, AS TO THE RESULTS TO BE EXPECTED FROM USE OF ANY OF THE
   INVENTIONS CONTAINED IN THE TECHNOLOGY OR FROM MANUFACTURE OR SALE OF ANY
   PRODUCT, AND LICENSOR EXPRESSLY DISCLAIMS ALL WARRANTIES AND GUARANTEES,
   EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, THE IMPLIED WARRANTIES OF
   MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. LICENSOR SHALL HAVE NO
   RESPONSIBILITY UNDER ANY LEGAL PRINCIPLE TO LICENSEE, ITS SUBLICENSEE OR TO
   OTHERS FOR THE ABILITY OF LICENSEE OR ITS SUBLICENSEE TO USE THE TECHNOLOGY;
   FOR THE QUALITY, QUANTITY OR PERFORMANCE OF ANY PRODUCTS MANUFACTURED UNDER
   THE TECHNOLOGY; FOR THE CLAIMS OF THIRD PARTIES RELATING TO ANY PRODUCTS
   MANUFACTURED OR SOLD BY LICENSEE; OR FOR ANY FAILURE IN PRODUCTION, DESIGN OR
   OPERATION OF ANY PRODUCT MANUFACTURED OR SOLD BY LICENSEE. IN NO EVENT SHALL
   LICENSOR BE LIABLE TO LICENSEE OR ITS SUBLICENSEE FOR ANY DAMAGES, INCLUDING
   ALL DIRECT, INDIRECT, SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES (INCLUDING
   LOST PROFITS) UNDER THIS AGREEMENT OR OTHERWISE.

[ * ] = Certain confidential information contained in this document, marked by
        brackets, has been omitted and filed separately with the Securities and
        Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange
        Act of 1934, as amended.
<PAGE>

 .  Dispute Resolution
   -----------------

   Should any dispute between Licensor and Licensee arise under this agreement,
   Licensor and Licensee, through appropriately senior executives, shall first
   meet and attempt to resolve the dispute in face-to-face negotiations. This
   meeting shall occur within [ * ] of the time the dispute arises.

   If no resolution is reached, Licensor and Licensee shall, within [ * ] of the
   first meeting, attempt to settle the dispute by formal mediation. If the
   parties cannot agree upon a mediator and the place of mediation, the
   mediation shall be administered by the American Arbitration Association in
   Research Triangle Park, North Carolina.

   If no resolution is reached through formal mediation, the dispute shall be
   resolved by binding arbitration before a three-arbitrator panel, administered
   by the American Arbitration Association, with limited discovery. Each party
   shall select one of the arbitrators and those arbitrators shall select the
   third.

   The venue shall be either Research Triangle Park, North Carolina if the
   notice of intent to arbitrate the dispute is first given by Licensee or
   Seattle, Washington if the notice of intent to arbitrate is first given by
   Licensor and the governing law shall be that of the State of North Carolina
   in either instance, without giving effect to conflict of law considerations.
   In no event shall punitive or exemplary damages o attorney's fees be
   awardable and each party shall be responsible for it's own attorney's fees.

   Notwithstanding the foregoing dispute resolution and governing law
   provisions, Licensor and Licensee shall each retain the right to seek
   judicial injunctive and other equitable relief where appropriate.

[ * ] = Certain confidential information contained in this document, marked by
        brackets, has been omitted and filed separately with the Securities and
        Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange
        Act of 1934, as amended.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00025-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00025-of-00352.parquet"}]]